耳念珠菌致病及耐药机制的研究进展  

Mechanisms of pathogenesis and drug resistance in Candida auris

作　　者：赵伟娜 张冰 王启明 ZHAO WeiNa;ZHANG Bing;WANG QiMing(School of Life Sciences,Hebei University,Baoding 071002,China)

机构地区：[1]河北大学生命科学学院,保定071002

出　　处：《中国科学：生命科学》2021年第9期1254-1263,共10页Scientia Sinica(Vitae)

基　　金：国家自然科学基金(批准号:31770018,31961133020)资助。

摘　　要：耳念珠菌(Candida auris),又称耳道假丝酵母,是2009年被发现的一种病原真菌,有"超级真菌"之称,特点是较难在临床中鉴别、易在患者皮肤中定植,大多数菌株在医疗环境中可以持久生存,具有多重耐药性等,致使临床病症难以治疗及流行难以控制.耳念珠菌对三类主要的抗真菌药物--唑类药物、多烯类药物和棘白菌素类药物通常都具有单一或多重耐药性,且耐药性程度不尽相同,这大大增加了临床治疗的难度.耳念珠菌在过去十年中迅速流行,在世界多地引发了重大的感染疫情,对全球的公共卫生健康造成了严重的威胁.本文主要阐述了耳念珠菌的致病和耐药机制.The superbug fungus,Candida auris,is an emerging fungal pathogen discovered in 2009.It is characterized by difficulty in identification,easy colonization in patient’s skin tissue,long-lasting survival in a medical environment,multiple drug resistance for most isolates,etc.,resulting in diseases that are difficult to treat and control.C.auris usually exhibits drug resistance to one or more of the three main antifungal drugs—azoles,polyenes,and echinocandins—with varying degrees of resistance,leading to difficulty in treatment.In the past decade,C.auris has spread worldwide,causing major infections at healthcare institutions,and is becoming a global threat to public health.Thus,this review describes the pathogenesis and drug resistance of C.auris.

关 键 词：耳念珠菌 多重耐药性 生物膜 ERG11 

分 类 号：R446.5[医药卫生—诊断学]